Glaukos (GKOS) Stock Forecast & Price Target

Glaukos Corp has demonstrated significant growth in its glaucoma revenue, with a 45% year-over-year increase in 3Q25, surpassing consensus expectations and indicating strong market demand for its iDose product and other offerings. The company's operating margin improved markedly, rising 1,210 basis points year-over-year, which is a favorable indicator of operational efficiency and profitability. Additionally, Glaukos's Corneal Health segment has exhibited consistent growth with a compound annual growth rate (CAGR) of approximately 15.2% globally, further supporting a robust outlook for the company's future financial performance.

Glaukos Corp's financial outlook is significantly challenged by several factors, including a projected decline in Corneal Health revenues and a decrease in Legacy Surgical Glaucoma sales, which fell by 4.7% to $40.8 million. The company faces further risk from slower adoption rates of its new product offerings, such as iDose and infinite, as well as increased competition from a growing number of market entrants. Additionally, potential changes in the reimbursement environment and slower-than-expected product launches could further exacerbate Glaukos’s revenue challenges, leading to a negative outlook for its stock.